Nirogy Therapeutics rises with USD 16.5 Million to target metabolite transporters
Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules for targeting cellular transporters, announced the closing of a USD 16.5 million Series A financing.
Nirogy plans to use the proceeds to improve its drug discovery platform for generating a pipeline of small-molecule drugs designed to aim the solute carrier family of transporter proteins (SLCTs) embedded in the cell membrane. SLCTs are gatekeepers of vital physiological functions, comprising nutrient uptake and metabolite disposal, aberrantly altered in many diseases. Nirogy is d...
